Price Action Don’t Lie: It Seems Albany Molecular Research, Inc. Will Go Up. Have Another Big Increase

Price Action Don't Lie: It Seems Albany Molecular Research, Inc. Will Go Up. Have Another Big Increase

The stock of Albany Molecular Research, Inc. (NASDAQ:AMRI) is a huge mover today! The stock increased 2.97% or $0.49 during the last trading session, hitting $17. About 429,736 shares traded hands or 77.65% up from the average. Albany Molecular Research, Inc. (NASDAQ:AMRI) has risen 12.01% since February 29, 2016 and is uptrending. It has underperformed by 0.21% the S&P500.
The move comes after 8 months positive chart setup for the $739.08 million company. It was reported on Oct, 4 by We have $26.52 PT which if reached, will make NASDAQ:AMRI worth $413.88 million more.

Analysts await Albany Molecular Research, Inc. (NASDAQ:AMRI) to report earnings on November, 3. They expect $0.26 earnings per share, up 136.36% or $0.15 from last year’s $0.11 per share. AMRI’s profit will be $11.30 million for 16.35 P/E if the $0.26 EPS becomes a reality. After $0.32 actual earnings per share reported by Albany Molecular Research, Inc. for the previous quarter, Wall Street now forecasts -18.75% negative EPS growth.

According to Zacks Investment Research, “Albany Molecular Research is an integrated provider of drug discovery and development, chemistry research and manufacturing services. They offer services traditionally provided by chemistry divisions within pharmaceutical and biotechnology companies, including drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. Recently, they expanded their service offerings to include commercial manufacturing through their strategic relationship with and investment in Organichem Corporation.”

Insitutional Activity: The institutional sentiment increased to 1.44 in Q2 2016. Its up 0.49, from 0.95 in 2016Q1. The ratio improved, as 12 funds sold all Albany Molecular Research, Inc. shares owned while 31 reduced positions. 12 funds bought stakes while 50 increased positions. They now own 27.11 million shares or 11.37% less from 30.58 million shares in 2016Q1.
Moreover, Pnc Gp Inc has 0% invested in Albany Molecular Research, Inc. (NASDAQ:AMRI) for 84 shares. State Board Of Administration Of Florida Retirement Sys holds 12,318 shares or 0% of its portfolio. Putnam Invs Lc accumulated 278,759 shares or 0.01% of the stock. Bessemer Group last reported 0.01% of its portfolio in the stock. New York State Common Retirement Fund owns 24,400 shares or 0% of their US portfolio. California State Teachers Retirement owns 54,496 shares or 0% of their US portfolio. Moreover, Ngam Ltd Partnership has 0.03% invested in Albany Molecular Research, Inc. (NASDAQ:AMRI) for 171,297 shares. Alliancebernstein L P holds 0% or 28,950 shares in its portfolio. Goldman Sachs Group Incorporated owns 82,522 shares or 0% of their US portfolio. Sei last reported 44 shares in the company. Tower Research Cap Limited Liability Corp (Trc) accumulated 0% or 677 shares. Citadel Ltd Limited Liability Company has 0% invested in the company for 79,516 shares. Strs Ohio holds 0% or 47,400 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 593 shares. Gsa Prtnrs Llp, a United Kingdom-based fund reported 70,127 shares.

Insider Transactions: Since May 31, 2016, the stock had 0 insider buys, and 2 selling transactions for $93,471 net activity. 1,401 shares were sold by Hagen Steven R, worth $21,421. $72,050 worth of Albany Molecular Research, Inc. (NASDAQ:AMRI) was sold by OCONNOR KEVIN on Tuesday, May 31.

More notable recent Albany Molecular Research, Inc. (NASDAQ:AMRI) news were published by: which released: “Update in Lawsuit for Investors in Albany Molecular Research, Inc. shares …” on August 23, 2016, also with their article: “Albany Molecular Research, Inc.’s (AMRI) CEO William Marth on Q2 2016 Results …” published on August 04, 2016, published: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” on August 09, 2016. More interesting news about Albany Molecular Research, Inc. (NASDAQ:AMRI) were released by: and their article: “Moody’s affirms Albany Molecular’s B3 CFR following announced acquisition of …” published on May 09, 2016 as well as‘s news article titled: “Federal lawsuit filed against Albany drug developer” with publication date: December 03, 2014.

AMRI Company Profile

Albany Molecular Research, Inc., incorporated on August 6, 1998, is a global contract research and manufacturing company. The Firm provides drug discovery, development, and manufacturing services. The Firm operates through three divisions: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM). The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small-scale commercial manufacturing. API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized injectable formulations. The Firm supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs, as well as research, development and manufacturing for the agrochemical and other industries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment